The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1191
September 13, 2004
View Complete Issue         Table of Contents 2019 
Vytorin: A Combination of Ezetimibe and Simvastatin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vytorin: A Combination of Ezetimibe and Simvastatin
September 13, 2004 (Issue: 1191)
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vytorin: A Combination of Ezetimibe and Simvastatin
Article code: 1191a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.